Parallel Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Parallel Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25	Closed	-$2.55K	–	3518
2023 Q2	$2.55K	Hold	25	–	–	﹤0.01%	2682
2023 Q1	$2.27K	Buy	+25	New	+$1.47K	﹤0.01%	2719
2022 Q1	–	Sell	-3	Closed	–	–	3375
2021 Q4	$0	Sell	3 -83	-97%	-$6.42K	﹤0.01%	3374
2021 Q3	$9K	Buy	86 +42	+95%	+$4.92K	﹤0.01%	2148
2021 Q2	$6K	Sell	44 -31	-41%	-$3.5K	﹤0.01%	2264
2021 Q1	$7K	Buy	75 +68	+971%	+$7.93K	﹤0.01%	2091
2020 Q4	$1K	Hold	7	–	–	﹤0.01%	2522
2020 Q3	$1K	Sell	7 -6	-46%	-$750	﹤0.01%	2523
2020 Q2	$2K	Buy	+13	New	+$1.98K	﹤0.01%	2261

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Parallel Advisors's RETA Position: Q3 2023 in Review

Parallel Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 25 shares — an estimated $2.55K sold.

Parallel Advisors first reported a position in RETA in Q2 2020 and held it in 9 quarters. The position peaked at $9K in Q3 2021. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Parallel Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Parallel Advisors sold 25 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $2.55K.
Parallel Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020 and held it in 9 quarters.
Parallel Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $9K in Q3 2021.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Parallel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.